The Drug-Induced Respiratory Disease Website and App

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.k Exogenous lipoid pneumonia (subacute, acute)

I. Interstitial/parenchymal lung disease

I.n ILD with a granulomatous component

I. Interstitial/parenchymal lung disease

I.t A mass or masses

I. Interstitial/parenchymal lung disease

I.u Pneumoconiosis (silicosis, talcosis...)

II. Pulmonary edema - Acute lung injury - ARDS

II.a Pulmonary edema, noncardiogenic (NCPE)

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

IV. Airway involvement

IV.b Severe or catastrophic bronchospasm or asthma attack (can be fatal)

IV. Airway involvement

IV.ae Cough syncope

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.c Upper airway obstruction other than angioedema or hematoma

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.i Thermal (burns, frostbite), chemical or caustic injury on the face, mouth, tongue, pharynx or upper airway

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.aj Nasal, palatal and/or pharyngeal pathology

VI. Pleural and/or pericardial involvement

VI.f Pneumothorax

VI. Pleural and/or pericardial involvement

VI.r Empyema

VI. Pleural and/or pericardial involvement

VI.ac Pneumothorax, bilateral

VII. Pulmonary vasculopathy

VII.b Pulmonary arterial hypertension

VII. Pulmonary vasculopathy

VII.c Pulmonary veno-occlusive disease

VII. Pulmonary vasculopathy

VII.g Foreign body pulmonary vasculopathy (Excipient lung disease)

VII. Pulmonary vasculopathy

VII.i Acute pulmonary hypertension

VII. Pulmonary vasculopathy

VII.j Mercury pulmonary embolism

VII. Pulmonary vasculopathy

VII.q Septic pulmonary embolism

VII. Pulmonary vasculopathy

VII.r Pulmonary artery aneurysm(s)

VIII. Mediastinal involvement

VIII.h Pneumomediastinum

VIII. Mediastinal involvement

VIII.i Mediastinitis

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.a Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.s Botulism (foodborne-, wound-)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.ah Acute myelopathy (can cause ARF)

X. Systemic/Distant conditions, syndromes and reactions

X.o Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

X. Systemic/Distant conditions, syndromes and reactions

X.w Multiple organ dysfunction/failure (MODS/MOF)

X. Systemic/Distant conditions, syndromes and reactions

X.ae Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS)

X. Systemic/Distant conditions, syndromes and reactions

X.bc Foreign body (talc, cornstarch) retinopathy

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XI. Miscellaneous

XI.h Aspiration, aspiration pneumonia (w/wo demonstrable pharyngeal dysmotility)

XI. Miscellaneous

XI.k Pulmonary emphysema - Lung cysts or bullae

XI. Miscellaneous

XI.o Death following exposure or poisoning

XII. Cardiovascular involvement / toxicity

XII.h Coronary artery disease (acute) - Myocardial ischemia/infarction

XII. Cardiovascular involvement / toxicity

XII.j Endocarditis (infective)

XII. Cardiovascular involvement / toxicity

XII.x Hypertrophic cardiomyopathy

XVI. Imaging

XVI.d Imaging: Alveolar opacities or haze with a batwing or butterfly distribution

XVI. Imaging

XVI.u Imaging: A miliary pattern (diffuse random micronodules)

XVI. Imaging

XVI.v Imaging: Centrilobular micronodules (can be diffuse)

XVI. Imaging

XVI.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

XVI. Imaging

XVI.ad Imaging: Lung cysts or bullae (see also XVI ah/bf)

XVI. Imaging

XVI.ag Imaging: A pattern similar to pneumoconiotic progressive massive fibrosis (PMF)

XVI. Imaging

XVI.ak Imaging: A 'tree-in-bud' pattern

XVII. Distinctive patterns - 'Eye-catchers'

XVII.t Eye catcher: Purpuric/Ecchymotic/Cyanotic lesions of the earlobes and/or nose

XVII. Distinctive patterns - 'Eye-catchers'

XVII.u Eye catcher: Talc retinopathy

XVII. Distinctive patterns - 'Eye-catchers'

XVII.x Eye catcher: A batwing pattern on imaging

XIX. Pathology

XIX.j Path: Micronodular organizing pneumonia/BOOP

XIX. Pathology

XIX.ab Path: Foreign body deposits/granulomatous reaction

XIX. Pathology

XIX.ac Path: Pneumoconiosis (silicosis, talcosis, talcoma)

XIX. Pathology

XIX.an Path: Foreign body embolism, microangiopathy, vasculopathy

XIX. Pathology

XIX.ax Path: Pulmonary hypertension incl. angiomatoid vasculopathy

XX. Infections & related conditions

XX.a Respiratory tract infection incl. pneumonia

XX. Infections & related conditions

XX.b Opportunistic pulmonary/systemic infections

XX. Infections & related conditions

XX.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

XX. Infections & related conditions

XX.p Lung abscess/abscesses (see also VIr)

XX. Infections & related conditions

XX.s Sternoclavicular septic arthritis

XX. Infections & related conditions

XX.t Epidural abscess

XX. Infections & related conditions

XX.ak Osteomyelitis (notably of thoracic bones)

I. Interstitial/parenchymal lung disease

I.k Exogenous lipoid pneumonia (subacute, acute)

I. Interstitial/parenchymal lung disease

I.o Pulmonary alveolar proteinosis (PAP)

II. Pulmonary edema - Acute lung injury - ARDS

II.b Pulmonary edema, cardiogenic

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

II. Pulmonary edema - Acute lung injury - ARDS

II.h Hypoxemia, low oxygen saturation (may occur in isolation)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

IV. Airway involvement

IV.ad Transient hacking cough

VII. Pulmonary vasculopathy

VII.e Fat/oil embolism - The FES embolism syndrome

X. Systemic/Distant conditions, syndromes and reactions

X.w Multiple organ dysfunction/failure (MODS/MOF)

XII. Cardiovascular involvement / toxicity

XII.a Left or biventricular dysfunction/failure

XII. Cardiovascular involvement / toxicity

XII.c Pericardial effusion (w/wo tamponade)

XII. Cardiovascular involvement / toxicity

XII.g Cardiomyopathy (acute, subacute, chronic)

XII. Cardiovascular involvement / toxicity

XII.h Coronary artery disease (acute) - Myocardial ischemia/infarction

XII. Cardiovascular involvement / toxicity

XII.n Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

XII. Cardiovascular involvement / toxicity

XII.p Coronary artery disease (subacute, chronic)

XII. Cardiovascular involvement / toxicity

XII.x Hypertrophic cardiomyopathy

XII. Cardiovascular involvement / toxicity

XII.ak Cardiotoxicity

XIX. Pathology

XIX.n Path: Pulmonary alveolar proteinosis pattern (PAP pattern)

XIX. Pathology

XIX.z Path: Exogenous lipoid pneumonia

XIX. Pathology

XIX.ci Path: Pulmonary peliosis

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.k Exogenous lipoid pneumonia (subacute, acute)

I. Interstitial/parenchymal lung disease

I.ag Chemical (toxic) pneumonitis

II. Pulmonary edema - Acute lung injury - ARDS

II.a Pulmonary edema, noncardiogenic (NCPE)

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.b Pneumorenal syndrome (w/wo ANCAs)

IV. Airway involvement

IV.h Reactive airway dysfunction syndrome (RADS)

IV. Airway involvement

IV.x Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)

IV. Airway involvement

IV.ag Obstructive airway dysfunction (see also IVc, XVx)

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.c Upper airway obstruction other than angioedema or hematoma

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.f Vocal cord dysfunction, adduction, closure, injury

VI. Pleural and/or pericardial involvement

VI.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

X. Systemic/Distant conditions, syndromes and reactions

X.o Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

X. Systemic/Distant conditions, syndromes and reactions

X.w Multiple organ dysfunction/failure (MODS/MOF)

X. Systemic/Distant conditions, syndromes and reactions

X.ae Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS)

XI. Miscellaneous

XI.p Sniffing death - Death from inhalation of compound

XII. Cardiovascular involvement / toxicity

XII.u Cardiac- cardiorespiratory/pulmonary arrest

XIV. Hemoglobinopathies - Abnormal hemoglobin states (acquired)

XIV.a Methemoglobinemia

XIV. Hemoglobinopathies - Abnormal hemoglobin states (acquired)

XIV.c Sulfhemoglobinemia

XVI. Imaging

XVI.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

XIX. Pathology

XIX.al Path: Acute/subacute bronchiolitis (see also IVc, IVi)

XX. Infections & related conditions

XX.p Lung abscess/abscesses (see also VIr)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.k Exogenous lipoid pneumonia (subacute, acute)

I. Interstitial/parenchymal lung disease

I.n ILD with a granulomatous component

I. Interstitial/parenchymal lung disease

I.o Pulmonary alveolar proteinosis (PAP)

I. Interstitial/parenchymal lung disease

I.v Relapsing or migrating pneumonitis/pneumonia (see also Id)

I. Interstitial/parenchymal lung disease

I.w Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

I. Interstitial/parenchymal lung disease

I.ax Persistent reduction in diffusing capacity for CO upon resolution of the adverse effect

I. Interstitial/parenchymal lung disease

I.ay Chronic pneumonitis

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

II. Pulmonary edema - Acute lung injury - ARDS

II.u Acute respiratory failure (e.g. from ARDS, ILD, PIE, OP, pulmonary edema or bronchospasm) requiring ECMO

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.c Hemoptysis

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.m Coagulopathy

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

IV. Airway involvement

IV.b Severe or catastrophic bronchospasm or asthma attack (can be fatal)

IV. Airway involvement

IV.e Deterioration/exacerbation of preexisting asthma or COPD

IV. Airway involvement

IV.h Reactive airway dysfunction syndrome (RADS)

IV. Airway involvement

IV.j Bronchiectasis

IV. Airway involvement

IV.l Large airway inflammation - Tracheitis (w/wo tissue eosinophilia)

IV. Airway involvement

IV.p Thermal, chemical or caustic airway injury

IV. Airway involvement

IV.u Sptutum production - Bronchorrhea - 'Bronchitis'

IV. Airway involvement

IV.ab Cough (lone)

IV. Airway involvement

IV.af Sputum production - Bonchorrhea - ‘Bronchitis’

IV. Airway involvement

IV.ag Obstructive airway dysfunction (see also IVc, XVx)

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.i Thermal (burns, frostbite), chemical or caustic injury on the face, mouth, tongue, pharynx or upper airway

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.p Foreign body in the airway

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.am Epiglottitis

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.ao Facial/labial/buccal/oral/dental trauma

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.aq Airway foreign body

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.av Gross tracheal inflammation on endoscopy

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.ax Tracheitis including eosinophilic tracheal inflammation

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.az Tracheal redness/inflammation on gross endoscopic examination

VI. Pleural and/or pericardial involvement

VI.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

VI. Pleural and/or pericardial involvement

VI.f Pneumothorax

VIII. Mediastinal involvement

VIII.a Lymphadenopathy (intrathoracic)

VIII. Mediastinal involvement

VIII.e Granulomatous mediastinal lymphadenopathy

VIII. Mediastinal involvement

VIII.h Pneumomediastinum

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.h Dyspnea, unexplained otherwise

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.af Seizures

X. Systemic/Distant conditions, syndromes and reactions

X.b Antiphospholipid antibodies w/wo the APL syndrome

X. Systemic/Distant conditions, syndromes and reactions

X.m Sarcoid-like granulomatosis (endo-/extrathoracic)

X. Systemic/Distant conditions, syndromes and reactions

X.s Systemic inflammatory response

X. Systemic/Distant conditions, syndromes and reactions

X.as Relapse or flare of preexisting ulcerative colitis

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XI. Miscellaneous

XI.o Death following exposure or poisoning

XI. Miscellaneous

XI.z Thermal skin/dermal injury

XI. Miscellaneous

XI.at Chest tightness

XI. Miscellaneous

XI.aw Polycythemia

XI. Miscellaneous

XI.ax Nicotine poisoning

XI. Miscellaneous

XI.ay Burns

XII. Cardiovascular involvement / toxicity

XII.a Left or biventricular dysfunction/failure

XII. Cardiovascular involvement / toxicity

XII.n Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

XII. Cardiovascular involvement / toxicity

XII.ai Bradycardia

XIV. Hemoglobinopathies - Abnormal hemoglobin states (acquired)

XIV.a Methemoglobinemia

XVI. Imaging

XVI.a Imaging: Diffuse haze

XVI. Imaging

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

XVI. Imaging

XVI.d Imaging: Alveolar opacities or haze with a batwing or butterfly distribution

XVI. Imaging

XVI.g Imaging: Diffuse whiteout/alveolar shadowing (see also under IIb-ARDS)

XVI. Imaging

XVI.k Imaging: An area or areas of consolidation

XVI. Imaging

XVI.v Imaging: Centrilobular micronodules (can be diffuse)

XVI. Imaging

XVI.ad Imaging: Lung cysts or bullae (see also XVI ah/bf)

XVI. Imaging

XVI.ak Imaging: A 'tree-in-bud' pattern

XVI. Imaging

XVI.bp Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan

XVII. Distinctive patterns - 'Eye-catchers'

XVII.x Eye catcher: A batwing pattern on imaging

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.a BAL: An excess proportion of lymphocytes

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.b BAL: An excess proportion of neutrophils

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.c BAL: An excess proportion of eosinophils

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.d BAL: Gross or microscopic bleeding/hemorrhage

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.f BAL: Foamy macrophages

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.i BAL: Oil red O-stainable material in BAL macrophages othen than exogenous lipids

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.n BAL: Brown-pigmented macrophages

XIX. Pathology

XIX.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XIX. Pathology

XIX.e Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

XIX. Pathology

XIX.f Path: ILD with a granulomatous component (see also Im)

XIX. Pathology

XIX.l Path: Giant-cell interstitial pneumonia (GIP)-pattern

XIX. Pathology

XIX.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XIX. Pathology

XIX.r Path: Alveolar hemorrhage (see also IIIa)

XIX. Pathology

XIX.z Path: Exogenous lipoid pneumonia

XIX. Pathology

XIX.al Path: Acute/subacute bronchiolitis (see also IVc, IVi)

XIX. Pathology

XIX.ap Path: Respiratory bronchiolitis (w/wo the RB-ILD-pattern)

XIX. Pathology

XIX.bc Path: Pulmonary capillaritis

XIX. Pathology

XIX.bx Path: Granulomatous lymphadenopathy

XX. Infections & related conditions

XX.a Respiratory tract infection incl. pneumonia

XX. Infections & related conditions

XX.c Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)

XX. Infections & related conditions

XX.h Nontuberculous pulmonary mycobacterial infection/superinfection

XX. Infections & related conditions

XX.ab Actinomycosis

I. Interstitial/parenchymal lung disease

I.k Exogenous lipoid pneumonia (subacute, acute)

XI. Miscellaneous

XI.p Sniffing death - Death from inhalation of compound

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.k Exogenous lipoid pneumonia (subacute, acute)

I. Interstitial/parenchymal lung disease

I.aa An area or areas of consolidation

I. Interstitial/parenchymal lung disease

I.af Hydrocarbon pneumonitis

I. Interstitial/parenchymal lung disease

I.ag Chemical (toxic) pneumonitis

I. Interstitial/parenchymal lung disease

I.ah Fire-eater's lung/pneumonitis

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.c Hemoptysis

IV. Airway involvement

IV.j Bronchiectasis

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.i Thermal (burns, frostbite), chemical or caustic injury on the face, mouth, tongue, pharynx or upper airway

VI. Pleural and/or pericardial involvement

VI.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XI. Miscellaneous

XI.p Sniffing death - Death from inhalation of compound

XIV. Hemoglobinopathies - Abnormal hemoglobin states (acquired)

XIV.a Methemoglobinemia

XVI. Imaging

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

XVI. Imaging

XVI.f Imaging: Bibasilar opacities/shadowing

XVI. Imaging

XVI.k Imaging: An area or areas of consolidation

XVI. Imaging

XVI.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

XVI. Imaging

XVI.ai Imaging: Pneumatoceles (see also XVIaf)

XVI. Imaging

XVI.aj Imaging: Pneumatocele or pneumatoceles

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.a BAL: An excess proportion of lymphocytes

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.h BAL: Exogenous (oil red O-stainable) lipids in BAL macrophages

XIX. Pathology

XIX.cd Path: Fire eater's lung

XX. Infections & related conditions

XX.p Lung abscess/abscesses (see also VIr)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.k Exogenous lipoid pneumonia (subacute, acute)

I. Interstitial/parenchymal lung disease

I.o Pulmonary alveolar proteinosis (PAP)

I. Interstitial/parenchymal lung disease

I.u Pneumoconiosis (silicosis, talcosis...)

I. Interstitial/parenchymal lung disease

I.ao Hypersensitivity pneumonitis pattern

I. Interstitial/parenchymal lung disease

I.ap Pulmonary infiltrates

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.c Hemoptysis

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

IV. Airway involvement

IV.ab Cough (lone)

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.w Uvulitis, uvular edema

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.ar Oropharyngeal erosion/bleeding

VI. Pleural and/or pericardial involvement

VI.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

VI. Pleural and/or pericardial involvement

VI.f Pneumothorax

VI. Pleural and/or pericardial involvement

VI.ac Pneumothorax, bilateral

VIII. Mediastinal involvement

VIII.h Pneumomediastinum

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.d Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis)

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

X. Systemic/Distant conditions, syndromes and reactions

X.ae Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS)

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XI. Miscellaneous

XI.k Pulmonary emphysema - Lung cysts or bullae

XI. Miscellaneous

XI.p Sniffing death - Death from inhalation of compound

XI. Miscellaneous

XI.as Deterioration of graft function in SOT recipients

XII. Cardiovascular involvement / toxicity

XII.c Pericardial effusion (w/wo tamponade)

XII. Cardiovascular involvement / toxicity

XII.d Myocarditis (can be fulminant)

XII. Cardiovascular involvement / toxicity

XII.h Coronary artery disease (acute) - Myocardial ischemia/infarction

XII. Cardiovascular involvement / toxicity

XII.n Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

XII. Cardiovascular involvement / toxicity

XII.t Heart block (bundle branch- or AV-)

XII. Cardiovascular involvement / toxicity

XII.y Asystole

XII. Cardiovascular involvement / toxicity

XII.ah Coronary vasospasm - Vasospastic angina

XII. Cardiovascular involvement / toxicity

XII.ar Coronary artery dissection

XVI. Imaging

XVI.m Imaging: Interlobular septal thickening

XVI. Imaging

XVI.ak Imaging: A 'tree-in-bud' pattern

XIX. Pathology

XIX.j Path: Micronodular organizing pneumonia/BOOP

XIX. Pathology

XIX.k Path: Desquamative interstitial pneumonia (DIP-pattern)

XIX. Pathology

XIX.n Path: Pulmonary alveolar proteinosis pattern (PAP pattern)

XIX. Pathology

XIX.z Path: Exogenous lipoid pneumonia

XIX. Pathology

XIX.ab Path: Foreign body deposits/granulomatous reaction

XIX. Pathology

XIX.ac Path: Pneumoconiosis (silicosis, talcosis, talcoma)

XX. Infections & related conditions

XX.a Respiratory tract infection incl. pneumonia

XX. Infections & related conditions

XX.c Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)

XX. Infections & related conditions

XX.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

XXI. Neoplastic conditions

XXI.a Lung cancer